Health-related quality of life of female sex workers living with HIV in South Africa: a cross-sectional study

Linwei Wang1, David W. Dowdy2, Carly A. Comins2, Katherine Young3, Mfezi Mcingana3, Ntambue Mulumba3, Hlengiwe Mhlophe3, Claire Chen2, Harry Hausler3, Sheree R. Schwartz2, Stefan Baral2, Sharmistha Mishra1,4,5,6,§ and the Siyaphambili Study team1,2,3

§ Corresponding author: Sharmistha Mishra, MAP-Centre for Urban Health Solutions, St. Michael’s Hospital, Unity Health Toronto, University of Toronto, 209 Victoria St, Toronto, ON M5B 1T8, Canada. (sharmistha.mishra@utoronto.ca)

Abstract
Introduction: Health-related quality of life (HRQoL) is an important HIV outcome beyond viral suppression. However, there are limited data characterizing HRQoL of key populations, including female sex workers (FSW) living with HIV.

Methods: We used baseline data (22 June 2018–23 March 2020) of FSW who were diagnosed with HIV and enrolled into a randomized trial in Durban, South Africa. HRQoL information was collected by a generic preference-accompanied tool with five domains (EQ-5D), and summarized into a single score (range 0–1), which represents health utility. We employed multi-variable beta regression models to identify determinants of HRQoL and to estimate subgroup-specific HRQoL score. Using external estimates of life expectancy and population size, we estimated the number of quality adjusted life years reduced among FSW living with HIV in South Africa associated with violence and drug use.

Results: Of 1,363 individuals (mean age: 32.4 years; mean HRQoL score: 0.857) in our analysis, 62.6% used drugs, 61.3% experienced physical or sexual violence and 64.6% self-reported taking antiretroviral treatment (ART). The following were associated with a reduction in the average marginal HRQoL score: older age (per decade: 0.018 [95% CI: 0.008, 0.027]), drug use (0.022 [0.007, 0.036]), experience of violence (0.024 [0.010, 0.038]) and moderate (vs. no) level of internalized stigma (0.023 [0.004, 0.041]). Current ART use was associated with a 0.015-point (–0.001, 0.031) increase in the HRQoL score. The estimated mean (95% CI) HRQoL scores ranged from 0.838 (0.816, 0.860) for FSW who used drugs, experienced violence and were not on ART; to 0.899 (0.883, 0.916) for FSW who did not use drugs nor experience violence and were on ART. Our results can be translated into a reduction in 37,184 and 39,722 quality adjusted life years related to drug use and experience of violence, respectively, in South Africa.

Conclusions: These results demonstrate the association of ART with higher HRQoL among FSW and the need to further address structural risks, including drug use, violence and stigma. Population-specific estimates of HRQoL score can be further used to calculate quality-adjusted life years in economic evaluations of individual and structural interventions addressing the needs of FSW living with HIV.

Clinical Trial Registration: NCT03500172 (April 17, 2018).

Keywords: female sex worker; HIV; health-related quality of life; health utility; drug use; violence; stigma

Additional information may be found under the Supporting Information tab of this article.

Received 25 June 2021; Accepted 19 January 2022

Copyright © 2022 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

1 INTRODUCTION

Globally, there has been remarkable progress towards the UNAIDS 90-90-90 HIV testing and treatment targets. By the end of 2019, 81% of people living with HIV (PLHIV) knew their status, of whom 83% were on antiretroviral treatment (ART), and 88% of those on ART were virally suppressed [1].

Although much work remains to improve the cascade of HIV care in order to achieve the new 95-95-95 targets by 2030 [2], there is growing recognition of the importance of patient-centred chronic care to improve patient-reported outcomes, such as health-related quality of life (HRQoL) [3,4]. Some have proposed that good HRQoL should be explicitly included as the “fourth” target as part of the HIV care cascade [4].
HRQoL is a multidimensional concept defined as a person’s subjective perception of the impact of ill health on daily life and includes physical, psychological and social functioning [5]. Most existing studies on HRQoL among PLHIV have identified CD4 count, gender, age and ART use as common determinants for HRQoL [6–9]. The majority of these studies have been conducted in wider populations of PLHIV in high-income settings [8], though some have been performed in low- and middle-income settings, including sub-Saharan Africa [7,8]. There is a dearth of research regarding HRQoL in key populations living with HIV in high prevalence settings, including among female sex workers (FSW).

In South Africa, FSW have a high burden of HIV [10]. Approximately 90,000 FSW in South Africa are living with HIV, representing nearly 60% of all women engaged in sex work [10]. FSW living with HIV face a wide range of challenges, including HIV progression, comorbidities, drug use, stigma, and other social and structural vulnerabilities [3,8], resulting in suboptimal treatment uptake and viral suppression [11–13]. Data, although limited, suggest that less than 40% of FSW living with HIV are virally suppressed [11]. However, it is unclear how these challenges have shaped FSW’s self-perception of their wellbeing. A meta-analysis across 31 studies in low- and middle-income settings found highly prevalent mental health conditions among FSW, including depression, anxiety, post-traumatic stress disorder, and suicidal thoughts and attempts [14]. However, these studies examined FSW in general, instead of PLHIV, and with a focus on mental health rather than HRQoL [14].

HRQoL as a multidimensional concept can also be summarized into a single metric of health utility, which is important for economic evaluations of HIV interventions [6,7,15]. For example, preference-accompanied measures of HRQoL, such as the EQ-5D (captures self-rated information in five domains – mobility, self-care, ability to do usual activities, pain/discomfort and anxiety/depression), and each domain is measured with three levels (1 = no problems, 2 = some/moderate problems and 3 = extreme problems). The answers can be assembled into a 5-digit health state reflecting the score on each dimension, resulting in a total of 243 plausible health states (3^5). EQ-5D also contains a separate question, which asks participants to directly rate their health state from the best (score of 100) to the worst (score of 0) (referred to as EQ visual analogue scale [EQ-VAS]). EQ-5D has been used to measure HRQoL of the wider population and PLHIV across settings, including South Africa [7,8,21,22]. EQ-5D is also a guideline-recommended instrument to derive health utility measures [15,23].

Our primary outcome was a summary HRQoL score, representing health utility. The HRQoL score was calculated using the 5-digit health states combined with valuations of the health states from the wider population (value set). A wider population value set is used to reflect the preferences of local taxpayers and potential receivers of healthcare [16]. We used the value set obtained from the population in Zimbabwe [21]. The calculated HRQoL score ranges between 0 and 1, where 0 represents a state equivalent to death and 1 represents perfect health.

Our secondary outcomes included EQ-VAS, each of the EQ-5D-3L measures and a binary variable indicating no reported problem on all five EQ-5D-3L domains (perfect health).

We defined an a priori set of covariates based on evidence from the literature regarding their associations with HRQoL [7,9,24]. These covariates included socio-demographics, clinical features and treatment of HIV, drug use, and other social and structural factors. Specifically, we considered age, race, education, ART experience, CD4 count, viral load, drug use in the past 30 days, lifetime injection drug use, experience of homelessness in the past 6 months, lifetime experience of physical or sexual violence, experience with stigma related to HIV or sex work and internalized stigma related to sex work. Details of each variable are shown in Table 1 and online Appendix A1.
RESULTS

First, we examined the descriptive characteristics of the study sample at baseline; assessed the distribution of our primary and secondary measures of HRQoL; and compared the differences in the HRQoL score, and of EQ-VAS, by covariates.

Second, we employed multivariable beta regression models with a complementary log-log link and fixed dispersion to investigate associations between covariates of interest and the HRQoL score [25]. Beta regression models provide a flexible approach to modelling health utility values, which are truncated and skewed [25]. We provide details on model selection in online Appendix A2. We present the results as average marginal effects along with 95% confidence intervals (CIs), which reflect the magnitude of association between a one-unit change in covariates and the mean HRQoL score [26].

Using the fitted model, we estimated the mean and 95% CIs of HRQoL score for subgroups of FSW defined by identified determinants of HRQoL score, setting the rest covariates at the sample average values. In addition, assuming an average remaining life expectancy of 30 years [27], and an estimated 90,000 FSW living with HIV in South Africa [10], using the observed prevalence of drug use and experience of violence, we estimated the number of QALYs related to drug use and experience of violence, respectively, in South Africa.

Third, we performed a set of multivariable regression analyses to examine the relationship between the covariates of interest and our secondary outcomes. Multivariable linear regression was used to model EQ-VAS. Multivariable logistic regression was used to model each of the EQ-5D-3L domains, and the perfect health state, separately. We grouped each EQ-5D-3L domain into two levels (reporting moderate/extreme vs. no problems).

Lastly, to examine the sensitivity of our results to the value set used, we computed a new HRQoL score using the value set obtain from the wider population in the UK [22]. We repeated the multivariable beta regression analysis to examine the relationship between covariates of interest and the new HRQoL score.

All statistical analyses were executed in R version 3.6.2. R package “eq5d” was used to calculate the HRQoL score [28], “betareg” was used for beta regression analysis [25] and “margins” was used to estimate average marginal effects [26].

3 RESULTS

Of 1,363 individuals included in our analysis, the majority (97.4%) self-identified as black, and the mean age was 32.4 years (standard deviation: 8.0; median: 31.0; and interquartile range: 26.6–36.7). We excluded 28 (2.0%) individuals because they were missing the primary outcome (online Figure A3.1 shows the details on exclusion). Overall, 853 individuals (62.6%) reported using drugs in the past 30 days, 835 (61.3%) ever experienced physical or sexual violence, 800 (64.6%) reported being on ART and 303 (22.2%) reported prior, but non-current ART use at the time of enrolment. According to blood tests conducted...
at study entry, 510 (37.4%) individuals were virally suppressed (<50 copies/ml). Table 1 provides details on sample characteristics.

Regarding the five domains of EQ-5D, the majority of individuals reported no problems in mobility (95.7%), self-care (99.0%) and usual activity (96.9%); while 32.9% and 40.7% reported at least some problems in pain/discomfort and anxiety/depression, respectively (Figure 1a). Of the 243 plausible health states summarized across EQ-5D domains, we observed 47; the 12 most frequent health states represented more than 95% of all observations (Figure 1b). Individuals with a perfect health state accounted for more than half (52.5%) of the sample (Figure 1b). The HRQoL score was heavily left-skewed, ranging from 0.233 to 1, with a median of 1 [interquartile range: 0.787,1] and mean of 0.857 (standard deviation: 0.187) (Figure 1c). EQ-VAS ranged from 0 to 100, with a median of 52.0 [50.0, 70.0] and mean of 57.7 (21.9) (Figure 1d).

Table 2 presents the summary statistics of HRQoL score and EQ-VAS by sample characteristic. The median HRQoL score was higher in younger individuals (1.00 vs. 0.854, comparing ages 18–34 vs. 35–64, p = 0.006); those identified as black (1.00 vs. 0.854, p = 0.008) and reported current ART use (1.00 vs. 0.854, p = 0.001). In contrast, the median HRQoL score was lower in individuals who used drugs (0.854 vs. 1.00, p<0.001), and who experienced homelessness (0.854 vs. 1.00, p = 0.014) or violence (0.854 vs. 1.00, p<0.001).

We did not observe a difference in HRQoL score by CD4 count nor by viral load. However, individuals with higher CD4 counts and lower viral load had higher EQ-VAS (p<0.001, Table 2); and those with experience of stigma or internalized stigma had lower EQ-VAS (p<0.001, Table 2).

In the multivariable regression analyses, we excluded another 87 (6.4%) individuals because they had missing covariate information (online Figure A3.1). Individuals excluded were younger, less likely to be on ART and more likely to experience homelessness compared to those included (online Table A3.1). We found that age (per 10-year increase), drug use and violence experience were associated with 0.018 (95% CI: 0.008, 0.027), 0.022 (0.007, 0.036) and 0.024 (0.010, 0.038) lower average marginal HRQoL score, respectively (Table 3). Current ART use was associated with 0.015 (~0.001, 0.031) higher average marginal HRQoL score (Table 3). We did not find a difference in HRQoL score between individuals who were ART naive and who had previously been but were not currently on ART (results not shown; we thus combined these two groups in models). Individuals with moderate internalized stigma had 0.023 (0.004, 0.041) lower average marginal HRQoL score compared to those without; however, we did not observe a difference between those with extreme versus no internalized stigma (Table 3).

We did not find independent associations between education, CD4 count, viral load, homelessness or stigma experience with HRQoL score (Table 3).
Table 2. EQ-5D health-related quality of life (HRQoL) score and visual analogue scale (EQ-VAS) among female sex workers living with HIV in Durban, South Africa, 2018–2020

| Characteristics                  | EQ-5D HRQoL score | EQ-VAS | p-value<sup>b</sup> | EQ-VAS | p-value<sup>b</sup> |
|----------------------------------|-------------------|--------|----------------------|--------|----------------------|
|                                  | Mean (SD)         | Median (IQR) |                     | Mean (SD)         | Median (IQR) |
| Total                            | 0.857 (0.187)     | 1.00 [0.787, 1.00] | 0.004               | 57.7 (21.9)       | 52.0 [50.0, 70.0] |
| Age in years                     |                   |         | 0.18                 |        |                      |
| 18–24                            | 0.891 (0.157)     | 1.00 [0.787, 1.00] | 0.004               | 57.5 (21.1)       | 53.0 [50.0, 70.0] |
| 25–34                            | 0.859 (0.189)     | 1.00 [0.787, 1.00] | 0.18                | 57.2 (22.2)       | 52.0 [50.0, 70.0] |
| 35–44                            | 0.846 (0.191)     | 0.854 [0.787, 1.00] | 0.854               | 57.5 (21.5)       | 52.0 [50.0, 70.0] |
| 45–65                            | 0.811 (0.210)     | 0.854 [0.727, 1.00] | 0.21                | 62.1 (21.8)       | 58.0 [50.0, 80.0] |
| Self-identified as black race    |                   |         | 0.97                 |        |                      |
| Yes                              | 0.859 (0.186)     | 1.00 [0.787, 1.00] | 0.008               | 57.8 (21.7)       | 52.0 [50.0, 70.0] |
| No                               | 0.776 (0.207)     | 0.854 [0.660, 1.00] | 0.31                | 56.3 (25.8)       | 55.5 [47.5, 74.3] |
| Completed secondary school or higher |                   |         |                      |        |                      |
| Yes                              | 0.866 (0.184)     | 1.00 [0.787, 1.00] |                      | 58.8 (24.7)       | 54.0 [47.0, 75.5] |
| No                               | 0.855 (0.188)     | 1.00 [0.787, 1.00] |                      | 57.5 (21.1)       | 52.0 [50.0, 70.0] |
| ART experience                   |                   |         | <0.001               |        |                      |
| ART naive                        | 0.842 (0.195)     | 0.854 [0.787, 1.00] | 0.004               | 54.2 (20.5)       | 51.0 [45.0, 62.0] |
| Currently off ART                | 0.827 (0.206)     | 0.854 [0.727, 1.00] | <0.001              | 49.1 (21.7)       | 50.0 [40.0, 60.0] |
| Currently on ART                 | 0.870 (0.177)     | 1.00 [0.787, 1.00] | <0.001              | 61.4 (21.2)       | 56.0 [50.0, 75.0] |
| CD4, cells/mm<sup>3</sup>        |                   |         | <0.001               |        |                      |
| ≥500                             | 0.855 (0.183)     | 1.00 [0.787, 1.00] | 0.76                | 59.4 (22.8)       | 54.0 [50.0, 75.0] |
| 350–499                          | 0.860 (0.196)     | 1.00 [0.787, 1.00] |                      | 57.6 (21.0)       | 52.0 [50.0, 70.0] |
| 200–349                          | 0.865 (0.175)     | 1.00 [0.787, 1.00] |                      | 53.6 (20.0)       | 50.0 [45.0, 62.0] |
| <200                             | 0.846 (0.204)     | 1.00 [0.787, 1.00] |                      | 55.7 (20.6)       | 52.0 [47.8, 70.0] |
| Viral load, copies/ml            |                   |         | <0.001               |        |                      |
| <50                              | 0.860 (0.180)     | 1.00 [0.787, 1.00] | 0.62                | 61.6 (21.7)       | 56.0 [50.0, 75.8] |
| 50–1000                          | 0.847 (0.192)     | 1.00 [0.744, 1.00] |                      | 57.4 (21.8)       | 51.0 [50.0, 70.0] |
| >1000                            | 0.859 (0.191)     | 1.00 [0.787, 1.00] |                      | 54.8 (21.6)       | 51.0 [45.0, 67.0] |
| Drug use, past 30 days           |                   |         | <0.001               |        | <0.001               |
| Yes                              | 0.844 (0.191)     | 0.854 [0.787, 1.00] | <0.001              | 55.8 (21.7)       | 51.0 [47.0, 70.0] |
| No                               | 0.879 (0.178)     | 1.00 [0.787, 1.00] | <0.001              | 61.0 (21.8)       | 56.0 [50.0, 75.0] |
| Injection drug use, ever         |                   |         | 0.082                |        |                      |
| Yes                              | 0.861 (0.177)     | 1.00 [0.787, 1.00] | 0.95                | 54.1 (17.6)       | 50.0 [45.0, 63.5] |
| No                               | 0.857 (0.187)     | 1.00 [0.787, 1.00] |                      | 57.8 (22.0)       | 52.0 [50.0, 70.0] |
| Homelessness, past 6 months      |                   |         | <0.001               |        | <0.001               |
| Yes                              | 0.840 (0.194)     | 0.854 [0.777, 1.00] | 0.014               | 54.5 (21.4)       | 51.0 [45.0, 65.0] |
| No                               | 0.864 (0.184)     | 1.00 [0.787, 1.00] | <0.001              | 59.1 (21.9)       | 54.0 [50.0, 72.0] |
| Experience of physical or sexual violence, ever |                   |         | <0.001               |        | <0.001               |
| Yes                              | 0.837 (0.197)     | 0.854 [0.777, 1.00] | <0.001              | 55.0 (21.4)       | 51.0 [47.0, 67.0] |
| No                               | 0.888 (0.165)     | 1.00 [0.787, 1.00] | <0.001              | 62.0 (21.9)       | 56.0 [50.0, 80.0] |
| Experience with stigma<sup>c</sup> |                   |         | 0.33                 |        | <0.001               |
| No                               | 0.858 (0.188)     | 1.00 [0.787, 1.00] |                      | 62.0 (22.5)       | 57.5 [50.0, 80.0] |
| Slight                           | 0.861 (0.189)     | 1.00 [0.787, 1.00] |                      | 60.0 (19.7)       | 53.5 [50.0, 71.0] |
| Moderate                         | 0.863 (0.184)     | 1.00 [0.787, 1.00] |                      | 54.5 (21.3)       | 51.0 [46.3, 69.0] |

(Continued)
Table 2. (Continued)

| Characteristics | EQ-5D HRQoL score | EQ-VAS |
|-----------------|-------------------|--------|
|                 | Mean (SD)         | Median (IQR) | p-value<sup>b</sup> | Mean (SD) | Median (IQR) | p-value<sup>b</sup> |
| Extreme         | 0.844 (0.186)     | 0.854 [0.787, 1.00] | 0.07 | 51.4 (22.5) | 50.0 [40.5, 61.5] | <0.001 |
| Internalized stigma<sup>d</sup> | No | 0.868 (0.178) | 1.00 [0.787, 1.00] | 60.0 (21.2) | 54.0 [50.0, 71.0] |
|                 | Slight | 0.858 (0.186) | 1.00 [0.787, 1.00] | 60.2 (21.2) | 55.0 [50.0, 73.8] |
|                 | Moderate | 0.830 (0.204) | 0.854 [0.787, 1.00] | 56.9 (22.2) | 52.0 [43.0, 70.0] |
|                 | Extreme | 0.867 (0.182) | 1.00 [0.787, 1.00] | 50.3 (22.2) | 50.0 [41.0, 60.0] |

Abbreviations: ART, antiretroviral treatment; EQ-5D, EuroQoL five dimension; IQR, interquartile range; SD, standard deviation.
<sup>a</sup>HQoL score was calculated using the Zimbabwe general population value set.
<sup>b</sup>Wilcoxon rank sum tests and Kruskal–Wallis tests were used to compare median values in the HRQoL score and EQ-VAS by binary variables and other categorical variables, respectively; p-value < 0.05 was denoted by bold font.
<sup>c</sup>HIV or sex work-related stigma, ever; details on stigma measures in online Appendix A1.
<sup>d</sup>Sex work related; details on stigma measures in online Appendix A1.

Table 3. Multivariable analyses of factors associated with the EQ-5D health-related quality of life (HRQoL) score and the visual analogue scale (EQ-VAS) of female sex workers living with HIV in Durban, South Africa, 2018–2020

| Characteristics                            | Average marginal change in EQ-5D HRQoL score<sup>a</sup> | Average marginal change in EQ-VAS<sup>b</sup> |
|--------------------------------------------|----------------------------------------------------------|------------------------------------------------|
|                                            | Point   | Lower  | Upper  | p-value<sup>e</sup> | Point   | Lower  | Upper  | p-value<sup>e</sup> |
| Age in years (per 10-year increase)        | -0.018  | -0.027 | -0.008 | <0.001 | 0.005  | -0.020 | 0.011  | 0.56 |
| Completed secondary school or higher (yes vs. no) | 0.006  | -0.011 | 0.022  | 0.49   | 0.014  | -0.015 | 0.043  | 0.35 |
| Current on ART (yes vs. no)                | 0.015   | -0.001 | 0.031  | 0.062  | 0.080  | 0.054  | 0.106  | <0.001 |
| CD4<200, cells/mm<sup>3</sup> (yes vs. no) | -0.002  | -0.023 | 0.019  | 0.85   | -0.011 | -0.046 | 0.024  | 0.54 |
| Viral suppression (<50 copies/ml) (yes vs. no) | -0.008  | -0.024 | 0.008  | 0.32   | 0.021  | -0.005 | 0.048  | 0.12 |
| Drug use, past 30 days (yes vs. no)        | -0.022  | -0.036 | -0.007 | 0.003  | -0.018 | -0.043 | 0.007  | 0.16 |
| Homelessness, past 6 months (yes vs. no)   | -0.008  | -0.024 | 0.007  | 0.29   | -0.027 | -0.053 | -0.001 | 0.041 |
| Experience of physical or sexual violence, ever (yes vs. no) | -0.024  | -0.038 | -0.010 | <0.001 | -0.036 | -0.060 | -0.012 | 0.003 |
| Experience with stigma (slight vs. no)<sup>c</sup> | 0.005  | -0.013 | 0.022  | 0.61   | -0.012 | -0.042 | 0.018  | 0.44 |
| Experience with stigma (moderate vs. no)<sup>c</sup> | 0.011  | -0.008 | 0.029  | 0.25   | -0.059 | -0.092 | -0.027 | <0.001 |
| Experience with stigma (extreme vs. no)<sup>c</sup> | -0.002  | -0.023 | 0.019  | 0.86   | -0.078 | -0.112 | -0.043 | <0.001 |
| Internalized stigma (slight vs. no)<sup>d</sup> | -0.008  | -0.026 | 0.010  | 0.37   | 0.000  | -0.031 | 0.031  | 1.000 |
| Internalized stigma (moderate vs. no)<sup>d</sup> | -0.023  | -0.041 | -0.004 | 0.016  | -0.042 | -0.072 | -0.012 | 0.006 |
| Internalized stigma (extreme vs. no)<sup>d</sup> | 0.0003  | -0.018 | 0.019  | 0.98   | -0.085 | -0.119 | -0.052 | <0.001 |

Abbreviations: ART, antiretroviral treatment; EQ-5D, EuroQoL five dimension.
<sup>a</sup>Estimated using beta regression with complementary log-log link; the HRQoL score was calculated using the Zimbabwe general population value set.
<sup>b</sup>Estimated using linear regression; EQ-VAS scaled to 0–1 from 0–100.
<sup>c</sup>HIV or sex work-related stigma, ever; details on stigma measures in online Appendix A1.
<sup>d</sup>Sex work related; details on stigma measures in online Appendix A1.
<sup>e</sup>P-value less than 0.05 was denoted by bold font.

Based on the fitted model, the estimated mean (95% CI) HRQoL scores were 0.870 (0.854, 0.886) for FSW living with HIV overall, 0.877 (0.862, 0.893) and 0.862 (0.843, 0.882) for those with and without current ART use, respectively. Figure 2 shows estimates of HRQoL score for other subgroups of FSW. For example, the model estimated mean HRQoL scores of 0.838 (0.816, 0.860) for FSW who used drugs, experienced violence and were not on ART, versus 0.899 (0.883, 0.916) for FSW who did not use drugs nor experience violence and were on ART. Our results can be translated into a
Drug use: yes/Experience violence: yes
Drug use: no/Experience violence: yes
Drug use: yes/Experience violence: no
Drug use: no/Experience violence: no

Overall

0.800 0.825 0.850 0.875 0.900 0.925
Estimated mean and 95% CI of HRQoL score

Subgroups of FSW

Current ART use

No
Yes

0.886 (0.865–0.907)
0.864 (0.842–0.886)
0.862 (0.839–0.884)
0.864 (0.842–0.886)

Figure 2. Estimated mean and 95% confidence intervals of health-related quality of life (HRQoL) score (representing health utility) for subgroups of female sex workers (FSW) living with HIV in Durban, South Africa by current antiretroviral treatment (ART) use. Values estimated using the fitted multivariable beta regression model, setting the rest of covariates (age, education, CD4 count, viral suppression, homelessness, experience with stigma and internalized stigma) at the sample average values.

There has been limited study of HRQoL among FSW living with HIV across sub-Saharan Africa, including the estimation of health utility. Among 1,363 FSW who were diagnosed with HIV and enrolled into an adaptive randomized trial via HIV prevention and treatment program for sex workers in Durban, we found older age, lack of ART use, drug use, experience of violence and moderate (vs. no) level of internalized stigma were associated with lower HRQoL score at the time of enrolment. In addition, we present the overall and subgroup-specific estimates of HRQoL scores, which can be used to calculate QALYs in cost-utility analysis of interventions focused on FSW living with HIV in South Africa.

Our sensitivity analysis using a UK-based value set revealed similar results (online Table A3.2).

4 | DISCUSSION

reduction in 37,184 and 39,722 QALYs related to drug use and violence experience, respectively, in South Africa.

Multivariable analyses of secondary HRQoL outcomes identified some similarities and differences in terms of variables associated HRQoL (Table 3; online Figure A3.2). For example, age and drug use were not independently associated with EQ-VAS (Table 3). Homelessness was associated with lower EQ-VAS (−0.027 [−0.053, −0.001]) (Table 3). We observed a dose–response relationship between both stigma variables and EQ-VAS, where increasing stigma was associated with lower EQ-VAS (Table 3). When we analysed the five domains of EQ-5D separately, we found that homelessness was associated with increased odds of reporting any problem in mobility (1.72 [0.95, 3.09]) and in pain/discomfort (1.46 [1.11, 1.90]) (online Figure A3.2).

Our sensitivity analysis using a UK-based value set revealed similar results (online Table A3.2).
Though none of these studies directly estimated HRQoL as a measure of health utility [14]. The associations between lower HRQoL and drug use, as well as experience of violence, were also consistent with this recent meta-analysis [14]. Lower HRQoL associated with experience of violence may reflect pain and psychologic effects (e.g. depression or post-trauma syndrome) of violence [29]. Lower HRQoL associated with drug use may reflect self-medication as a coping strategy in the context of chronic pain or depression [30,31], and/or reflect mental health effects of chronic use of drugs [31]. The high prevalence of drug use (62.6%) and experience of violence (61.3%) among FSW living with HIV, and their associations with lower HRQoL further demonstrate the synergistic epidemics of substance abuse, violence and HIV/AIDS (SAVA syndemic) among women [29,32], and highlight the need for integrated services to prevent and mitigate the effects of violence and drug use to help improve the wellbeing among sex workers.

We also observed a high prevalence of homelessness (29%) and experience of stigma or internalized stigma (88%) among FSW living with HIV in the study. Although we did not observe an independent association between experience of homelessness or stigma with HRQoL score, homelessness was associated with increased odds of reporting problems in mobility, pain/discomfort, as well as lower EQ-VAS. We also found a strong negative dose–response relationship between levels of stigma and the EQ-VAS. These findings suggest a strong negative subjective experience of stigma, even if this experience is not reflected in self-reported problems on the EQ-SD domains. Although generic preference-accompanied measures of HRQoL, such as EQ-5D, allow for calculation of HRQoL scores, which enables comparison across groups with different diseases, these measures do not capture other aspects of HRQoL, such as social relationships, spirituality and environment (e.g. physical safety and security) [33], and may be insensitive to specific issues faced by specific populations [34]. Moreover, HRQoL score is calculated by valuing individual’s self-rated health state from a wider population’s perspective of health preference, which contrasts with EQ-VAS, reflecting purely individual’s subjective perception of health [16]. Other reasons underlying the non-monotonic relationship (although not statistically significant) between stigma and self-reported problems on the EQ-5D domains may include the following: stigma may be associated with individual’s definition/perception of ‘having a problem’/tolerance levels of the problem [35]; as well as individual’s tendency to provide socially desirable answers [36]. Future studies using disease-specific HRQoL measures, such as the WHOQOL-HIV BREF [33], and exploring various underlying types of stigma [37] may provide additional insights into the relationship between stigma and HRQoL among FSW living with HIV. Our findings of high prevalence of stigma and its association with poorer self-perceived overall HRQoL further highlight the need to evaluate interventions to combat intersectional stigma (e.g. the convergence of multiple stigmatized attributes) for key populations [38].

Despite heterogeneity in HRQoL across subgroups of FSW living with HIV, we found that current ART use was independently associated with higher HRQoL. These results are consistent with previous studies among the wider population [7,15,24], including studies with longitudinal design, which found improvement in HRQoL following ART initiation [39]. For example, among a random sample of the wider adult population in South Africa, Thomas et al. showed that there was no difference in HRQoL among individuals on ART compared to HIV-negative individuals [24]. Collectively, these findings demonstrate the association between ART and higher HRQoL among PLHIV, and the importance of improving ART retention.

We did not observe an independent association between CD4 count or viral load with HRQoL in our study. Although HRQoL scores (utility measures) for PLHIV are often stratified by CD4 count (with lower CD4 counts correlated with lower weights), these estimates were obtained before ART became widely available [6]. Indeed, in the United States, more recent utility estimates have been found to be more similar across CD4 count strata and to have a narrower range than pre-ART measures [6]. Studies have shown that virally suppressed individuals still experience high levels of symptom-related distress, such as fatigue and energy loss, insomnia, sadness and depression, sexual dysfunction and changes in body appearance [40], which likely reduce their HRQoL. These results support that viral suppression is an essential but not sole end point of HIV care, and there is a need to improve HIV outcomes beyond viral suppression [3,4].

Our study has several limitations. Our sample did not include FSW living with HIV who were either undiagnosed or diagnosed recently. However, a previous study in South Africa has shown similar HRQoL score between those undiagnosed and those on ART [24]. As such, one might be able to approximate the HRQoL score for FSW living with undiagnosed HIV using our estimates of FSW on ART. Our results could be subject to selection bias to the extent that women reached by the sex worker programs and who consented to enrol into the study were different from their counterparts. Nevertheless, it is essential to study HRQoL in marginalized populations, such as FSW in high-burden countries. We relied on individuals’ self-report of ART use, which might be affected by recall bias. In addition, we used the EQ-5D health state valuations from Zimbabwe, as valuations for South Africa were not available. Our sensitivity analyses using UK valuations produced similar results. Moreover, Zimbabwe value set was obtained in 2000 [21]. Individual preferences for health states might have changed over time. However, the same value set was commonly used to calculate HRQoL scores across populations in South Africa [24], facilitating the comparison of our estimates against others. Our analyses were based on cross-sectional data and thus cannot be used to infer causality. Caution should be exercised when applying our estimates to FSW populations in different settings.

5 | CONCLUSIONS

In summary, we evaluated the overall and characteristics associated with HRQoL for FSW living with HIV in South Africa and presented both overall and subgroup-specific estimates of HRQoL score, representing health utility. The findings here reinforce the importance for HIV and sex worker programs to develop and adopt a comprehensive and human-centred
approach, with tailored services designed to address social and structural vulnerabilities, including drug use, violence and stigma, to improve HRQoL among FSW living with HIV. In addition, the monitoring of HRQoL could provide an actionable measure during program evaluation, and thus inform service adaptation or scale-up to improve the overall wellbeing among FSW living with HIV.

AUTHORS’ AFFILIATIONS
1MAP-Centre for Urban Health Solutions, St. Michael’s Hospital, Unity Health Toronto, Toronto, Ontario, Canada; 2Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA; 3TB HIV Care, Cape Town, South Africa; 4Institute of Medical SciencesUniversity of Toronto, Toronto, Ontario, Canada; 5Division of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; 6Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada

ACKNOWLEDGEMENTS
We are grateful to the Community Advisory Group of female sex workers in Durban who have shared their time, experiences, and expertise to inform the design and implementation of the study. Research reported in this publication was supported by the National Institute of Nursing Research of the National Institutes of Health under Award Number R01NR016650 as well as through support from the Johns Hopkins University Center for AIDS Research through the National Institutes of Health (award P30AI094189). The contents expressed here are the sole responsibility of the authors and may not represent the views of the NIH. Finally, we are grateful to the Centers for Disease Control and Prevention for their support of the TB HIV Care sex work program.

COMPETING INTERESTS
There are no competing interests to disclose.

AUTHOR’S CONTRIBUTION
All listed authors contributed significantly to the work. LW and SM conceptualized and designed the study. CAC, KY, MM, NM and HM contributed to the data collection. LW and CAC cleaned the data. CC provided critical inputs into data cleaning. LW conducted the data analyses, interpreted the results and drafted the manuscript. DW and SM provided critical inputs into the analyses. CAC, KY, MM, NM, HM, CC, HH, SRS, SB and SM contributed to the interpretation of results and provided critical manuscript revision. KY, MM, NM, HM and HH provided important inputs from local programming perspectives.

FUNDING
This study was funded by the National Institute of Nursing Research of the National Institutes of Health (R01NR016650), and Center for AIDS Research, Johns Hopkins University through the National Institutes of Health (P30AI094189).

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the author (SB), upon reasonable request and approval.

REFERENCES
1. UNAIDS. Global AIDS update 2020. Seizing the moment: tackling entrenched inequalities to end epidemics. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2020.
2. HIV/AIDS JUNPo. Understanding fast-track: accelerating action to end the AIDS epidemic by 2030. Switzerland: 2015.
3. Lancet HIV. Living well with HIV. Lancet HIV. 2019;6(12):e807.
4. Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, Del Amo Valero J, et al. Beyond viral suppression of HIV—the new quality of life frontier. BMC Med. 2016;14(1):94.
5. Ferrans CE. Definitions and conceptual models of quality of life. In: Lipscomb JGC, Snyder C, editors. Outcomes assessment in cancer. Cambridge: Cambridge University; 2005. p. 14–30.
6. Whitham HK, Hutchinson AB, Shrestha RK, Kuppermann M, Grund B, Shouse RL, et al. Health utility estimates and their application to HIV prevention in the United States: implications for cost-effectiveness modeling and future research needs. MDM Policy Pract. 2020;5(2):230146820936219.
7. Robertstad B, Olsen JA. The health related quality of life of people living with HIV/AIDS in sub-Saharan Africa — a literature review and focus group study. Cost Eff Resour Alloc. 2010;8:5.
8. Cooper VCJ, Harding R, Whetham J. Measuring quality of life among people living with HIV: a systematic review of reviews. Health Qual Life Outcomes. 2017;15(1):220.
9. Drewes J, Gusy B, Ruden U. More than 20 years of research into the quality of life of people with HIV and AIDS—a descriptive review of study characteristics and methodological approaches of published empirical studies. J Int Assoc Provid AIDS Care. 2013;12(1):18–22.
10. Baral S, Boyer C, Muesing K, Potela T, Wirtz AL, Decker MR, et al. Burden of HIV among female sex workers in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(7):588–49.
11. Comins CA, Schwartz SR, Petthu DR, Guddera V, Young K, Farley JE, et al. Siyaphambili protocol: an evaluation of randomized, nurse-led adaptive HIV treatment interventions for cisgender female sex workers living with HIV in Durban, South Africa. Res Nurs Health. 2019;42(2):107–18.
12. Comins CA, Schwartz SR, Young K, Mishra S, Guddera V, McInanga M, et al. Contextualising the lived experience of sex workers living with HIV in South Africa: a call for a human-centred response to sexual and reproductive health and rights. Sex Reprod Health Matters. 2019;27(1):1686200.
13. Schwartz S, Lambert A, Phaswana-Mafuya N, Kose Z, McInanga M, Holland C, et al. Engagement in the HIV care cascade and barriers to antiretroviral therapy uptake among female sex workers in Port Elizabeth, South Africa: findings from a respondent-driven sampling study. Sex Transm Infect. 2017;93(4):290–6.
14. Beattie TS, Silenova B, Krishnaratne S, Mazzuca A. Mental health problems among female sex workers in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003297.
15. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.
16. EuroQol Research Foundation. EQ-5D-3L User Guide. Basic information on how to use the EQ-5D-3L instrument. Version 6.0. 2018.
17. Zhou T, Guan H, Wang L, Zhang Y, Rui M, Ma A. Health-related quality of life in patients with different diseases measured with the EQ-5D-3L: a systematic review. Front Public Health. 2021;9:65523.
18. Tran BX, Ohinmaa A, Nguyen LT. Quality of life profile and psychometric properties of the EQ-5D-3L in HIV/AIDS patients. Health Qual Life Outcomes. 2012;10:132.
19. Feng YS, Kohlmann T, Janssen MF, Buchholz I. Psychometric properties of the EQ-5D-3L: a systematic review of the literature. Qual Life Res. 2021;30(3):647–73.
20. Rinaldi G, Kiadaliri AA, Haighparast-Bidgoli H. Cost effectiveness of HIV and sexual reproductive health interventions targeting sex workers: a systematic review. Cost Eff Resour Alloc. 2018;16:63.
21. Jehsma J, Hansen K, De Weerdt W, De Cock P, Kind P. How do Zimbabweans value health states? Popul Health Metr. 2003;1(1):11.
22. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.
23. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. London: 2013.
24. Thomas R, Burger R, Harper A, Kanema S, Mwenge L, Vamk C, et al. Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. Lancet Glob Health. 2017;5(11):e1133–41.
25. Cribari-Neto F, Zeileis A. Beta regression in R. 2009.
26. Thomas JL. Interpreting regression results using average marginal effects with R's margins. 2021.
27. World & Bank Data country profile: South Africa. Available from: https://databank.worldbank.org/views/reports/reportwadget.aspx;Report_Name=CountryProfile&id=b450d5f72b9a8+&add=1&nt=m+n&ccountry=ZAF. Accessed May 31, 2021.
28. Morton F, Nijjar J. eq5d: methods for analysing ‘EQ-5D’ data and calculating ‘EQ-5D’ index scores. CRAN Repository; 2021.
29. Meyer JP, Springer SA, Altice FL. Substance abuse, violence, and HIV in women: a literature review of the syndemic. J Womens Health (Larchmt). 2011;20(7):991–1006.
30. Allen C, Murphy A, Kiselbach S, VandenBerg S, Wiebe E. Exploring the experience of chronic pain among female survival sex workers: a qualitative study. BMC Fam Pract. 2015;16:182.
31. Ross S, Peselow E. Co-occurring psychotic and addictive disorders: neurobiology and diagnosis. Clin Neuropharmacol. 2012;35(5):235–43.
32. Gilbert L, Raj A, Hien D, Stockman J, Terlikbayeva A, Wyatt G. Targeting the SAVA (Substance Abuse, Violence, and AIDS) syndemic among women and girls: a global review of epidemiology and integrated interventions. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S118–27.
33. World Health Organization. WHOQOL-HIV BREF. Geneva: World Health Organization; 2002.
34. Clayson DJ, Wild DJ, Quartermar P, Duprat-Lomom I, Kubin M, Coons SJ. A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics. 2006;24(8):751–65.
35. Boring BL, Walsh KT, Naravaty N, Ng BW, Mathur VA. How and why patient concerns influence pain reporting: a qualitative analysis of personal accounts and perceptions of others’ use of numerical pain scales. Front Psychol. 2021;12:2232.
36. Haghighat R. The development of an instrument to measure stigmatization: factor analysis and origin of stigmatization. Eur J Psychiatry. 2005;19(3):144–54.
37. Grosso AL, Ketende SC, Stahlman S, Ky-Zerbo O, Ouedraogo HG, Kouanda S, et al. Development and reliability of metrics to characterize types and sources of stigma among men who have sex with men and female sex workers in Togo and Burkina Faso. BMC Infect Dis. 2019;19(1):208.
38. Andersson GZ, Reinius M, Eriksson LE, Svedhem V, Esfahani FM, Deuba K, et al. Stigma reduction interventions in people living with HIV to improve health-related quality of life. Lancet HIV. 2020;7(2):e129–40.
39. Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV AIDS (Auckl). 2012;4:117–24.
40. Erdbeer G, Sabranski M, Sonntag I, Stoehr HA, Plettenberg A, et al. Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy. J Int AIDS Soc. 2014;17(4 Suppl 3):19673.

SUPPORTING INFORMATION

Additional information may be found under the Supporting Information tab for this article:

Appendix